Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
STRO Stock Chart & Stats
$15.64
-$0.05(-2.48%)
At close: 4:00 PM EST
$15.64
-$0.05(-2.48%)
Day’s Range― - ―
52-Week Range$5.24 - $21.25
Previous CloseN/A
Volume326.60K
Average Volume (3M)987.85K
Market Cap
$133.24M
Enterprise Value$91.62M
Total Cash (Recent Filing)$167.59M
Total Debt (Recent Filing)$17.66M
Price to Earnings (P/E)―
Beta3.83
Next Earnings
Mar 12, 2026EPS Estimate
-8.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.70
Shares Outstanding8,519,392
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.17
Price to Sales (P/S)2.28
P/FCF Ratio-0.73
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue0.87
Enterprise Value/Gross Profit0.87
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$20.00Price Target Upside27.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressDosing of the first cohort in the Phase 1 basket trial of STRO-004 marks transition from IND clearance to human testing, validating clinical progression of the lead ADC program.
Manufacturing And CollaborationsProprietary cell-free ADC manufacturing combined with modular CDMO use and a collaboration with Astellas supports scalable optimization and can accelerate IND-enabling activities and external funding opportunities.
Preclinical DifferentiationPreclinical results indicate higher payload exposure and strong tumor regressions across multiple cancer models, supporting a potentially improved safety and efficacy profile versus competing TF-targeted ADCs.
Bears Say
Clinical Execution RiskUncertainty around dose optimization and indication prioritization raises risk that clinical dosing may take longer to reach exposure levels associated with preclinical efficacy, potentially delaying meaningful readouts.
Need For Clinical ValidationEncouraging preclinical data still require substantial clinical validation to confirm competitive differentiation against approved and emerging ADCs, leaving efficacy and safety as open questions.
Pipeline Setback And Market SkepticismDiscontinuation of luvelta in PROC and an analyst's reiterated Underperform rating underscore near-term pipeline setbacks and persistent market skepticism about near-term value creation.
Sutro Biopharma News
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $5.24 and its highest was $21.25 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Sutro Biopharma Inc’s market cap is $133.24M.
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Mar 12, 2026 which is in 43 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on Nov 06, 2025. The company reported -$6.7 earnings per share for the quarter, missing the consensus estimate of -$3.945 by -$2.755.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -8.16.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 8,519,392 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$6.7 in its last earnings report, missing expectations of -$3.945. Following the earnings report the stock price went down -13.362%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Currently, no hedge funds are holding shares in STRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sutro Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (27.88% Upside)
$20.00 (27.88% Upside)
Hedge Fund Trend
Increased
By 29.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.43%
12-Months-Change
Fundamentals
Return on Equity
-1810.01%
Trailing 12-Months
Asset Growth
-46.35%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
STRO Stock 12 Month Forecast
Average Price Target
$20.00
▲(27.88% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---